Loading clinical trials...

UNKNOWNNA

Communication by Brain - Computer Interface in Amyotrophic Lateral Sclerosis:Feasibility Study

NCT01897818•Centre Hospitalier Universitaire de Nice

Summary

ALS is a severe progressive neurodegenerative disease characterized by degeneration motor neurons leading to death in 3 to 5 years. Gradually in time, the patient deprived of all motor skills as well as the possibility of communication written and oral developing a state close Locked In Syndrome (LIS). The main objective is to establish the feasibility of brain-computer interface using the pathological condition, with dependent disabled subjects as a means of communication.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•age \>= 18
•have a diagnosis of ALS suspected, possible, probable with EMG
•be able to follow the study process and to comply with the schedule of visits upon entry into the study
•understand the purpose of the study
•expressing P300 wave in the conditions of the study

Exclusion Criteria

•have a mental illness or clinical dementia defined clinically significant may hinder the patient's ability to follow the procedures of the study
•have a significant history of photosensitive epilepsy
•have a history of allergy to the gel used for the electrodes
•Major protected by law (guardianship, curators)
•have uncorrectable visual disorders
•not being able to maintain a sitting position and focus on a computer screen for more than 30 min.

Locations (1)

Hôpital de l'Archet I

Nice, France

Key Dates

Start Date

July 1, 2013

Primary Completion Date

July 1, 2015

Last Updated

July 12, 2013

Enrollment

ESTIMATED participants

Conditions

Amyotrophic Lateral Sclerosis

Interventions

communication system P300 Speller

DEVICE

Contacts

Claude DESNUELLE, Pr

CONTACT

desnuelle.c@chu-nice.fr

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

NCT07322003

Amyotrophic Lateral Sclerosis

View study

RECRUITING

Intermuscular Coherence as a Biomarker for ALS

NCT05104710

Amyotrophic Lateral Sclerosis

View study

RECRUITING

UPenn Observational Research Repository on Neurodegenerative Disease

NCT04715399

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 12, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Communication by Brain - Computer Interface in Amyotrophic Lateral Sclerosis:Feasibility Study

Inclusion Criteria

Exclusion Criteria

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

Intermuscular Coherence as a Biomarker for ALS

UPenn Observational Research Repository on Neurodegenerative Disease

Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI)

Control Cohort CTRL COH

ASSESS ALL ALS Study